Lepu Biopharma Co Ltd
HKEX:2157
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lepu Biopharma Co Ltd
Operating Expenses
Lepu Biopharma Co Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lepu Biopharma Co Ltd
HKEX:2157
|
Operating Expenses
-¥850.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Operating Expenses
-¥27.2B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Operating Expenses
-¥10.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Operating Expenses
-¥2.7B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Operating Expenses
-¥3.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Operating Expenses
-¥1.9B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Lepu Biopharma Co Ltd
Glance View
Lepu Biopharma Co., Ltd. operates as an an innovation-driven biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-02-23. The firm mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The firm's products are sold at home and abroad.
See Also
What is Lepu Biopharma Co Ltd's Operating Expenses?
Operating Expenses
-850.6m
CNY
Based on the financial report for Dec 31, 2025, Lepu Biopharma Co Ltd's Operating Expenses amounts to -850.6m CNY.
What is Lepu Biopharma Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-14%
Over the last year, the Operating Expenses growth was -24%. The average annual Operating Expenses growth rates for Lepu Biopharma Co Ltd have been -6% over the past three years , -14% over the past five years .
